FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384300860> ?p ?o ?g. }

• W4384300860 abstract "The risk for cannabis use disorder (CUD) is elevated among U.S. adults with chronic pain, and CUD rates are disproportionately increasing in this group. Little is known about the role of medical cannabis laws (MCL) and recreational cannabis laws (RCL) in these increases. Among U.S. Veterans Health Administration (VHA) patients, we examined whether MCL and RCL effects on CUD prevalence differed between patients with and without chronic pain.Patients with ≥1 primary care, emergency, or mental health visit to the VHA and no hospice/palliative care within a given calendar year, 2005-2019 (yearly n=3,234,382 to 4,579,994) were analyzed using VHA electronic health record (EHR) data. To estimate the role of MCL and RCL enactment in the increases in prevalence of diagnosed CUD and whether this differed between patients with and without chronic pain, staggered-adoption difference-in-difference analyses were used, fitting a linear binomial regression model with fixed effects for state, categorical year, time-varying cannabis law status, state-level sociodemographic covariates, a chronic pain indicator, and patient covariates (age group [18-34, 35-64; 65-75], sex, and race and ethnicity). Pain was categorized using an American Pain Society taxonomy of painful medical conditions.In patients with chronic pain, enacting MCL led to a 0·14% (95% CI=0·12%-0·15%) absolute increase in CUD prevalence, with 8·4% of the total increase in CUD prevalence in MCL-enacting states attributable to MCL. Enacting RCL led to a 0·19% (95%CI: 0·16%, 0·22%) absolute increase in CUD prevalence, with 11·5% of the total increase in CUD prevalence in RCL-enacting states attributable to RCL. In patients without chronic pain, enacting MCL and RCL led to smaller absolute increases in CUD prevalence (MCL: 0·037% [95%CI: 0·03, 0·05]; RCL: 0·042% [95%CI: 0·02, 0·06]), with 5·7% and 6·0% of the increases in CUD prevalence attributable to MCL and RCL. Overall, MCL and RCL effects were significantly greater in patients with than without chronic pain. By age, MCL and RCL effects were negligible in patients age 18-34 with and without pain. In patients age 35-64 with and without pain, MCL and RCL effects were significant (p<0.001) but small. In patients age 65-75 with pain, absolute increases were 0·10% in MCL-only states and 0·22% in MCL/RCL states, with 9·3% of the increase in CUD prevalence in MCL-only states attributable to MCL, and 19.4% of the increase in RCL states attributable to RCL. In patients age 35-64 and 65-75, MCL and RCL effects were significantly greater in patients with pain.In patients age 35-75, the role of MCL and RCL in the increasing prevalence of CUD was greater in patients with chronic pain than in those without chronic pain, with particularly pronounced effects in patients with chronic pain age 65-75. Although the VHA offers extensive behavioral and non-opioid pharmaceutical treatments for pain, cannabis may seem a more appealing option given media enthusiasm about cannabis, cannabis commercialization activities, and widespread public beliefs about cannabis efficacy. Cannabis does not have the risk/mortality profile of opioids, but CUD is a clinical condition with considerable impairment and comorbidity. Because cannabis legalization in the U.S. is likely to further increase, increasing CUD prevalence among patients with chronic pain following state legalization is a public health concern. The risk of chronic pain increases as individuals age, and the average age of VHA patients and the U.S. general population is increasing. Therefore, clinical monitoring of cannabis use and discussion of the risk of CUD among patients with chronic pain is warranted, especially among older patients.Evidence before this study: Only three studies have examined the role of state medical cannabis laws (MCL) and/or recreational cannabis laws (RCL) in the increasing prevalence of cannabis use disorder (CUD) in U.S. adults, finding significant MCL and RCL effects but with modest effect sizes. Effects of MCL and RCL may vary across important subgroups of the population, including individuals with chronic pain. PubMed was searched by DH for publications on U.S. time trends in cannabis legalization, cannabis use disorders (CUD) and pain from database inception until March 15, 2023, without language restrictions. The following search terms were used: (medical cannabis laws) AND (pain) AND (cannabis use disorder); (recreational cannabis laws) AND (pain) AND (cannabis use disorder); (cannabis laws) AND (pain) AND (cannabis use disorder). Only one study was found that had CUD as an outcome, and this study used cross-sectional data from a single year, which cannot be used to determine trends over time. Therefore, evidence has been lacking on whether the role of state medical and recreational cannabis legalization in the increasing US adult prevalence of CUD differed by chronic pain status.Added value of this study: To our knowledge, this is the first study to examine whether the effects of state MCL and RCL on the nationally increasing U.S. rates of adult cannabis use disorder differ by whether individuals experience chronic pain or not. Using electronic medical record data from patients in the Veterans Health Administration (VHA) that included extensive information on medical conditions associated with chronic pain, the study showed that the effects of MCL and RCL on the prevalence of CUD were stronger among individuals with chronic pain age 35-64 and 65-75, an effect that was particularly pronounced in older patients ages 65-75.Implications of all the available evidence: MCL and RCL are likely to influence the prevalence of CUD through commercialization that increases availability and portrays cannabis use as 'normal' and safe, thereby decreasing perception of cannabis risk. In patients with pain, the overall U.S. decline in prescribed opioids may also have contributed to MCL and RCL effects, leading to substitution of cannabis use that expanded the pool of individuals vulnerable to CUD. The VHA offers extensive non-opioid pain programs. However, positive media reports on cannabis, positive online information that can sometimes be misleading, and increasing popular beliefs that cannabis is a useful prevention and treatment agent may make cannabis seem preferable to the evidence-based treatments that the VHA offers, and also as an easily accessible option among those not connected to a healthcare system, who may face more barriers than VHA patients in accessing non-opioid pain management. When developing cannabis legislation, unintended consequences should be considered, including increased risk of CUD in large vulnerable subgroups of the population." @default.
• W4384300860 created "2023-07-15" @default.
• W4384300860 creator A5006572902 @default.
• W4384300860 creator A5009849057 @default.
• W4384300860 creator A5015272156 @default.
• W4384300860 creator A5022705771 @default.
• W4384300860 creator A5024252619 @default.
• W4384300860 creator A5027797923 @default.
• W4384300860 creator A5029525341 @default.
• W4384300860 creator A5030024451 @default.
• W4384300860 creator A5034374546 @default.
• W4384300860 creator A5037098623 @default.
• W4384300860 creator A5038361898 @default.
• W4384300860 creator A5060699152 @default.
• W4384300860 creator A5078795152 @default.
• W4384300860 creator A5080186393 @default.
• W4384300860 creator A5088797464 @default.
• W4384300860 creator A5090402848 @default.
• W4384300860 creator A5092469957 @default.
• W4384300860 date "2023-07-12" @default.
• W4384300860 modified "2023-09-30" @default.
• W4384300860 title "Chronic Pain, Cannabis Legalization and Cannabis Use Disorder in Veterans Health Administration Patients, 2005 to 2019" @default.
• W4384300860 cites W1983041486 @default.
• W4384300860 cites W2029582040 @default.
• W4384300860 cites W2044200764 @default.
• W4384300860 cites W2122063286 @default.
• W4384300860 cites W2124478275 @default.
• W4384300860 cites W2140302476 @default.
• W4384300860 cites W2141617934 @default.
• W4384300860 cites W2202639059 @default.
• W4384300860 cites W2289546590 @default.
• W4384300860 cites W2516268678 @default.
• W4384300860 cites W2530593439 @default.
• W4384300860 cites W2554087526 @default.
• W4384300860 cites W2561559498 @default.
• W4384300860 cites W2600481469 @default.
• W4384300860 cites W2608549703 @default.
• W4384300860 cites W2767705998 @default.
• W4384300860 cites W2784557636 @default.
• W4384300860 cites W2789965462 @default.
• W4384300860 cites W2795772963 @default.
• W4384300860 cites W2807290966 @default.
• W4384300860 cites W2852302757 @default.
• W4384300860 cites W2885182602 @default.
• W4384300860 cites W2905788968 @default.
• W4384300860 cites W2908926404 @default.
• W4384300860 cites W2909769604 @default.
• W4384300860 cites W2921729278 @default.
• W4384300860 cites W2946421291 @default.
• W4384300860 cites W2949925729 @default.
• W4384300860 cites W2950460349 @default.
• W4384300860 cites W2972641553 @default.
• W4384300860 cites W2986974687 @default.
• W4384300860 cites W2990142185 @default.
• W4384300860 cites W2996157445 @default.
• W4384300860 cites W3002652673 @default.
• W4384300860 cites W3007607449 @default.
• W4384300860 cites W3008075220 @default.
• W4384300860 cites W3026114055 @default.
• W4384300860 cites W3035878800 @default.
• W4384300860 cites W3093575871 @default.
• W4384300860 cites W3124742002 @default.
• W4384300860 cites W3138985242 @default.
• W4384300860 cites W3157008346 @default.
• W4384300860 cites W3159062828 @default.
• W4384300860 cites W3165180375 @default.
• W4384300860 cites W3172201884 @default.
• W4384300860 cites W3174913206 @default.
• W4384300860 cites W3180839358 @default.
• W4384300860 cites W3202801136 @default.
• W4384300860 cites W3208673238 @default.
• W4384300860 cites W3211522649 @default.
• W4384300860 cites W4205720278 @default.
• W4384300860 cites W4206568653 @default.
• W4384300860 cites W4207015815 @default.
• W4384300860 cites W4220809577 @default.
• W4384300860 cites W4223535767 @default.
• W4384300860 cites W4225530318 @default.
• W4384300860 cites W4242455003 @default.
• W4384300860 cites W4247665917 @default.
• W4384300860 cites W4281768432 @default.
• W4384300860 cites W4282829968 @default.
• W4384300860 cites W4284958797 @default.
• W4384300860 cites W4285719527 @default.
• W4384300860 cites W4288077489 @default.
• W4384300860 cites W4290960183 @default.
• W4384300860 cites W4292749635 @default.
• W4384300860 cites W4293102929 @default.
• W4384300860 cites W4293833231 @default.
• W4384300860 cites W4308369850 @default.
• W4384300860 cites W4310131547 @default.
• W4384300860 cites W4311665057 @default.
• W4384300860 cites W4313650133 @default.
• W4384300860 cites W4320483188 @default.
• W4384300860 cites W4322720166 @default.
• W4384300860 cites W4376121352 @default.
• W4384300860 doi "https://doi.org/10.1101/2023.07.10.23292453" @default.
• W4384300860 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37503049" @default.
• W4384300860 hasPublicationYear "2023" @default.
• W4384300860 type Work @default.

• next